Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

4.710 -0.160 (-3.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Understanding ATAI Life Sciences's Unusual Options Activity ↗
On Wednesday, shares of ATAI Life Sciences (NASDAQ:ATAI) s... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
News headline image
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected ↗
Last week in Psychedelics: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low... 
Via Benzinga
News headline image
Another Psychedelic Stock Debuts, As This One Sets Up In A Base ↗
Field Trip Health dipped in its first day on the Nasdaq, making it the latest psychedelics company to hit a big U.S. exchange. 
Via Investor's Business Daily
News headline image
Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries ↗
Atai Life Sciences (NASDAQ:ATAI) is launching a new company 
Via Benzinga
News headline image
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance" ↗
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector. On Friday, 
Via Benzinga
News headline image
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex ↗
A number of financial firms and investment banks 
Via Benzinga
News headline image
Investment Banks Bullish On Psychedelics Co Atai Life Sciences: Cantor, Credit Suisse, Citigroup, Cowen, Aegis And Others Launch Coverage, Positive Ratings ↗
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: 
Via Benzinga
News headline image
Palo Santo: New Venture Capital Group Raises $35M To Focus On Psychedelic Medicine ↗
Palo Santo, a newly-created venture capital fund with an eye on psychedelic medicines, announced its official launch on Thursday. 
Via Benzinga
News headline image
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
News headline image
Post-COVID Investment Mega-Opportunity: Mental Health And Psychedelic Drug Stocks ↗
After governments have obsessed for the past 18 months about COVID-19, they are now forced to confront a much larger pandemic: the Mental Health Pandemic. This enormous crisis is also a huge investing... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021 ↗
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
Psychedelic Decriminalization Creating Market Opportunities
Via FinancialNewsMedia
Topics Cannabis Law Enforcement
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 ↗
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 ↗
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
News headline image
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
News headline image
The 6 Leading Psychedelic Stocks In Drug R&D ↗
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
Via FinancialNewsMedia
News headline image
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech ↗
It's off to a running start. 
Via The Motley Fool
News headline image
Atai IPO Day An Underwhelming Event ↗
The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform ↗
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Opening Day: WalkMe Stock Price Falls Following $287M IPO ↗
Backed by Insight Venture Partners, WalkMe fell as much as 7% in its trading debut earlier this week after a $287M initial public offering. According to filings, Insight will remain WalkMe's biggest... 
Via Talk Markets
Topics Initial Public Offering
News headline image
58 Biggest Movers From Friday ↗
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
News headline image
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public ↗
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.